Growth in Biologics Market Inspires Outsourcing
CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.
Biologics, including cell and gene therapies, have continued their upward trend in the pharmaceutical industry in the past few years. Pharma companies are investing in these therapies, and FDA has been encouraging the development of generic versions of already established biologics (1). Biologics, however, are costly to develop and manufacture, causing a variety of pharmaceutical companies to turn to contract development and manufacturing organizations (CDMOs). In response to this demand, CDMOs are continuing to invest in biopharmaceutical services and manufacturing facilities.
Read this article in BioPharm International's Partnerships for Outsourcing 2020 ebook.
Article Details
BioPharm International
eBook: Outsourcing Resources, February 2020
February 2020
Pages: 3–6
Citation
When referring to this article, please cite it as S. Haigney, “Growth in Biologics Market Inspires Outsourcing," BioPharm International Outsourcing Resources eBook (February 2020).
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
